

# Global Peptide Cancer Vaccine Market Size, Manufacturers, Opportunities and Forecast to 2030

<https://marketpublishers.com/r/GE302F0E81F8EN.html>

Date: April 2024

Pages: 108

Price: US\$ 3,450.00 (Single User License)

ID: GE302F0E81F8EN

## Abstracts

### Summary

Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.

According to APO Research, The global Peptide Cancer Vaccine market was estimated at US\$ million in 2023 and is projected to reach a revised size of US\$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.

North American market for Peptide Cancer Vaccine is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Peptide Cancer Vaccine is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Peptide Cancer Vaccine is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global manufacturers of Peptide Cancer Vaccine include Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech and GenereX Biotechnology, etc. In 2023, the world's top three vendors

accounted for approximately % of the revenue.

## Report Scope

This report aims to provide a comprehensive presentation of the global market for Peptide Cancer Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide Cancer Vaccine.

The Peptide Cancer Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue (\$ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Peptide Cancer Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

## Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Boston Biomedical

Ultimovacs

BrightPath Biotherapeutics

TapImmune

Immatics

Sellas

Imugene

VAXON Biotech

Generex Biotechnology

ISA Pharmaceuticals

OncoTherapy Science

#### Peptide Cancer Vaccine segment by Pipeline

ITK-1

GRN-1201

TPIV200

TPIV110

UV1

Galinpepimut-S

TARP 27-35

HER-Vaxx

Vx-001

Others

## Peptide Cancer Vaccine segment by Application

Breast Cancer

Lung Cancer

Melanoma

Prostate Cancer

Others

## Peptide Cancer Vaccine Segment by Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

## Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

## Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Cancer Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Cancer Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Cancer Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

## Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Peptide Cancer Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Peptide Cancer Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, Latin America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

## Contents

### 1 MARKET OVERVIEW

#### 1.1 Product Definition

#### 1.2 Global Market Growth Prospects

##### 1.2.1 Global Peptide Cancer Vaccine Market Size Estimates and Forecasts (2019-2030)

##### 1.2.2 Global Peptide Cancer Vaccine Sales Estimates and Forecasts (2019-2030)

#### 1.3 Peptide Cancer Vaccine Market by Pipeline

##### 1.3.1 ITK-1

##### 1.3.2 GRN-1201

##### 1.3.3 TPIV200

##### 1.3.4 TPIV110

##### 1.3.5 UV1

##### 1.3.6 Galinpepimut-S

##### 1.3.7 TARP 27-35

##### 1.3.8 HER-Vaxx

##### 1.3.9 Vx-001

##### 1.3.10 Others

#### 1.4 Global Peptide Cancer Vaccine Market Size by Pipeline

##### 1.4.1 Global Peptide Cancer Vaccine Market Size Overview by Pipeline (2019-2030)

##### 1.4.2 Global Peptide Cancer Vaccine Historic Market Size Review by Pipeline (2019-2024)

##### 1.4.3 Global Peptide Cancer Vaccine Forecasted Market Size by Pipeline (2025-2030)

#### 1.5 Key Regions Market Size by Type

##### 1.5.1 North America Peptide Cancer Vaccine Sales Breakdown by Pipeline (2019-2024)

##### 1.5.2 Europe Peptide Cancer Vaccine Sales Breakdown by Pipeline (2019-2024)

##### 1.5.3 Asia-Pacific Peptide Cancer Vaccine Sales Breakdown by Pipeline (2019-2024)

##### 1.5.4 Latin America Peptide Cancer Vaccine Sales Breakdown by Pipeline (2019-2024)

##### 1.5.5 Middle East and Africa Peptide Cancer Vaccine Sales Breakdown by Pipeline (2019-2024)

### 2 GLOBAL MARKET DYNAMICS

#### 2.1 Peptide Cancer Vaccine Industry Trends

#### 2.2 Peptide Cancer Vaccine Industry Drivers



2.3 Peptide Cancer Vaccine Industry Opportunities and Challenges

2.4 Peptide Cancer Vaccine Industry Restraints

### **3 MARKET COMPETITIVE LANDSCAPE BY COMPANY**

3.1 Global Top Players by Peptide Cancer Vaccine Revenue (2019-2024)

3.2 Global Top Players by Peptide Cancer Vaccine Sales (2019-2024)

3.3 Global Top Players by Peptide Cancer Vaccine Price (2019-2024)

3.4 Global Peptide Cancer Vaccine Industry Company Ranking, 2022 VS 2023 VS 2024

3.5 Global Peptide Cancer Vaccine Key Company Manufacturing Sites & Headquarters

3.6 Global Peptide Cancer Vaccine Company, Product Type & Application

3.7 Global Peptide Cancer Vaccine Company Commercialization Time

3.8 Market Competitive Analysis

3.8.1 Global Peptide Cancer Vaccine Market CR5 and HHI

3.8.2 Global Top 5 and 10 Peptide Cancer Vaccine Players Market Share by Revenue in 2023

3.8.3 2023 Peptide Cancer Vaccine Tier 1, Tier 2, and Tier

### **4 PEPTIDE CANCER VACCINE REGIONAL STATUS AND OUTLOOK**

4.1 Global Peptide Cancer Vaccine Market Size and CAGR by Region: 2019 VS 2023 VS 2030

4.2 Global Peptide Cancer Vaccine Historic Market Size by Region

4.2.1 Global Peptide Cancer Vaccine Sales in Volume by Region (2019-2024)

4.2.2 Global Peptide Cancer Vaccine Sales in Value by Region (2019-2024)

4.2.3 Global Peptide Cancer Vaccine Sales (Volume & Value), Price and Gross Margin (2019-2024)

4.3 Global Peptide Cancer Vaccine Forecasted Market Size by Region

4.3.1 Global Peptide Cancer Vaccine Sales in Volume by Region (2025-2030)

4.3.2 Global Peptide Cancer Vaccine Sales in Value by Region (2025-2030)

4.3.3 Global Peptide Cancer Vaccine Sales (Volume & Value), Price and Gross Margin (2025-2030)

### **5 PEPTIDE CANCER VACCINE BY APPLICATION**

5.1 Peptide Cancer Vaccine Market by Application

5.1.1 Breast Cancer

5.1.2 Lung Cancer

5.1.3 Melanoma

- 5.1.4 Prostate Cancer
- 5.1.5 Others
- 5.2 Global Peptide Cancer Vaccine Market Size by Application
  - 5.2.1 Global Peptide Cancer Vaccine Market Size Overview by Application (2019-2030)
  - 5.2.2 Global Peptide Cancer Vaccine Historic Market Size Review by Application (2019-2024)
  - 5.2.3 Global Peptide Cancer Vaccine Forecasted Market Size by Application (2025-2030)
- 5.3 Key Regions Market Size by Application
  - 5.3.1 North America Peptide Cancer Vaccine Sales Breakdown by Application (2019-2024)
  - 5.3.2 Europe Peptide Cancer Vaccine Sales Breakdown by Application (2019-2024)
  - 5.3.3 Asia-Pacific Peptide Cancer Vaccine Sales Breakdown by Application (2019-2024)
  - 5.3.4 Latin America Peptide Cancer Vaccine Sales Breakdown by Application (2019-2024)
  - 5.3.5 Middle East and Africa Peptide Cancer Vaccine Sales Breakdown by Application (2019-2024)

## **6 COMPANY PROFILES**

- 6.1 Boston Biomedical
  - 6.1.1 Boston Biomedical Company Information
  - 6.1.2 Boston Biomedical Business Overview
  - 6.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
  - 6.1.4 Boston Biomedical Peptide Cancer Vaccine Product Portfolio
  - 6.1.5 Boston Biomedical Recent Developments
- 6.2 Ultimovacs
  - 6.2.1 Ultimovacs Company Information
  - 6.2.2 Ultimovacs Business Overview
  - 6.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
  - 6.2.4 Ultimovacs Peptide Cancer Vaccine Product Portfolio
  - 6.2.5 Ultimovacs Recent Developments
- 6.3 BrightPath Biotherapeutics
  - 6.3.1 BrightPath Biotherapeutics Company Information
  - 6.3.2 BrightPath Biotherapeutics Business Overview

6.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio

6.3.5 BrightPath Biotherapeutics Recent Developments

6.4 TapImmune

6.4.1 TapImmune Company Information

6.4.2 TapImmune Business Overview

6.4.3 TapImmune Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.4.4 TapImmune Peptide Cancer Vaccine Product Portfolio

6.4.5 TapImmune Recent Developments

6.5 Immatics

6.5.1 Immatics Company Information

6.5.2 Immatics Business Overview

6.5.3 Immatics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Immatics Peptide Cancer Vaccine Product Portfolio

6.5.5 Immatics Recent Developments

6.6 Sellas

6.6.1 Sellas Company Information

6.6.2 Sellas Business Overview

6.6.3 Sellas Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Sellas Peptide Cancer Vaccine Product Portfolio

6.6.5 Sellas Recent Developments

6.7 Imugene

6.7.1 Imugene Company Information

6.7.2 Imugene Business Overview

6.7.3 Imugene Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.7.4 Imugene Peptide Cancer Vaccine Product Portfolio

6.7.5 Imugene Recent Developments

6.8 VAXON Biotech

6.8.1 VAXON Biotech Company Information

6.8.2 VAXON Biotech Business Overview

6.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.8.4 VAXON Biotech Peptide Cancer Vaccine Product Portfolio

6.8.5 VAXON Biotech Recent Developments

6.9 Generex Biotechnology

- 6.9.1 Generex Biotechnology Company Information
- 6.9.2 Generex Biotechnology Business Overview
- 6.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
- 6.9.4 Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
- 6.9.5 Generex Biotechnology Recent Developments
- 6.10 ISA Pharmaceuticals
  - 6.10.1 ISA Pharmaceuticals Company Information
  - 6.10.2 ISA Pharmaceuticals Business Overview
  - 6.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
  - 6.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
  - 6.10.5 ISA Pharmaceuticals Recent Developments
- 6.11 OncoTherapy Science
  - 6.11.1 OncoTherapy Science Company Information
  - 6.11.2 OncoTherapy Science Business Overview
  - 6.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
  - 6.11.4 OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
  - 6.11.5 OncoTherapy Science Recent Developments

## **7 NORTH AMERICA BY COUNTRY**

- 7.1 North America Peptide Cancer Vaccine Sales by Country
  - 7.1.1 North America Peptide Cancer Vaccine Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
  - 7.1.2 North America Peptide Cancer Vaccine Sales by Country (2019-2024)
  - 7.1.3 North America Peptide Cancer Vaccine Sales Forecast by Country (2025-2030)
- 7.2 North America Peptide Cancer Vaccine Market Size by Country
  - 7.2.1 North America Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030
  - 7.2.2 North America Peptide Cancer Vaccine Market Size by Country (2019-2024)
  - 7.2.3 North America Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030)

## **8 EUROPE BY COUNTRY**

- 8.1 Europe Peptide Cancer Vaccine Sales by Country
  - 8.1.1 Europe Peptide Cancer Vaccine Sales Growth Rate (CAGR) by Country: 2019

## VS 2023 VS 2030

8.1.2 Europe Peptide Cancer Vaccine Sales by Country (2019-2024)

8.1.3 Europe Peptide Cancer Vaccine Sales Forecast by Country (2025-2030)

## 8.2 Europe Peptide Cancer Vaccine Market Size by Country

8.2.1 Europe Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country:  
2019 VS 2023 VS 2030

8.2.2 Europe Peptide Cancer Vaccine Market Size by Country (2019-2024)

8.2.3 Europe Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030)

## 9 ASIA-PACIFIC BY COUNTRY

### 9.1 Asia-Pacific Peptide Cancer Vaccine Sales by Country

9.1.1 Asia-Pacific Peptide Cancer Vaccine Sales Growth Rate (CAGR) by Country:  
2019 VS 2023 VS 2030

9.1.2 Asia-Pacific Peptide Cancer Vaccine Sales by Country (2019-2024)

9.1.3 Asia-Pacific Peptide Cancer Vaccine Sales Forecast by Country (2025-2030)

### 9.2 Asia-Pacific Peptide Cancer Vaccine Market Size by Country

9.2.1 Asia-Pacific Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by  
Country: 2019 VS 2023 VS 2030

9.2.2 Asia-Pacific Peptide Cancer Vaccine Market Size by Country (2019-2024)

9.2.3 Asia-Pacific Peptide Cancer Vaccine Market Size Forecast by Country  
(2025-2030)

## 10 LATIN AMERICA BY COUNTRY

### 10.1 Latin America Peptide Cancer Vaccine Sales by Country

10.1.1 Latin America Peptide Cancer Vaccine Sales Growth Rate (CAGR) by Country:  
2019 VS 2023 VS 2030

10.1.2 Latin America Peptide Cancer Vaccine Sales by Country (2019-2024)

10.1.3 Latin America Peptide Cancer Vaccine Sales Forecast by Country (2025-2030)

### 10.2 Latin America Peptide Cancer Vaccine Market Size by Country

10.2.1 Latin America Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by  
Country: 2019 VS 2023 VS 2030

10.2.2 Latin America Peptide Cancer Vaccine Market Size by Country (2019-2024)

10.2.3 Latin America Peptide Cancer Vaccine Market Size Forecast by Country  
(2025-2030)

## 11 MIDDLE EAST AND AFRICA BY COUNTRY

## 11.1 Middle East and Africa Peptide Cancer Vaccine Sales by Country

11.1.1 Middle East and Africa Peptide Cancer Vaccine Sales Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030

11.1.2 Middle East and Africa Peptide Cancer Vaccine Sales by Country (2019-2024)

11.1.3 Middle East and Africa Peptide Cancer Vaccine Sales Forecast by Country (2025-2030)

## 11.2 Middle East and Africa Peptide Cancer Vaccine Market Size by Country

11.2.1 Middle East and Africa Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country: 2019 VS 2023 VS 2030

11.2.2 Middle East and Africa Peptide Cancer Vaccine Market Size by Country (2019-2024)

11.2.3 Middle East and Africa Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030)

## 12 VALUE CHAIN AND SALES CHANNELS ANALYSIS

### 12.1 Peptide Cancer Vaccine Value Chain Analysis

12.1.1 Peptide Cancer Vaccine Key Raw Materials

12.1.2 Key Raw Materials Price

12.1.3 Raw Materials Key Suppliers

12.1.4 Manufacturing Cost Structure

12.1.5 Peptide Cancer Vaccine Production Mode & Process

### 12.2 Peptide Cancer Vaccine Sales Channels Analysis

12.2.1 Direct Comparison with Distribution Share

12.2.2 Peptide Cancer Vaccine Distributors

12.2.3 Peptide Cancer Vaccine Customers

## 13 CONCLUDING INSIGHTS

## 14 APPENDIX

14.1 Reasons for Doing This Study

14.2 Research Methodology

14.3 Research Process

14.4 Authors List of This Report

14.5 Data Source

14.5.1 Secondary Sources

14.5.2 Primary Sources

14.6 Disclaimer

## List Of Tables

### LIST OF TABLES

- Table 1. Major Company of ITK-1
- Table 2. Major Company of GRN-1201
- Table 3. Major Company of TPIV200
- Table 4. Major Company of TPIV110
- Table 5. Major Company of UV1
- Table 6. Major Company of Galinpepimut-S
- Table 7. Major Company of TARP 27-35
- Table 8. Major Company of HER-Vaxx
- Table 9. Major Company of Vx-001
- Table 10. Major Company of Others
- Table 11. Global Peptide Cancer Vaccine Sales by Pipeline (2019 VS 2023 VS 2030) & (US\$ Million)
- Table 12. Global Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
- Table 13. Global Peptide Cancer Vaccine Sales Market Share in Volume by Pipeline (2019-2024)
- Table 14. Global Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (US\$ Million)
- Table 15. Global Peptide Cancer Vaccine Sales Market Share in Value by Pipeline (2019-2024)
- Table 16. Global Peptide Cancer Vaccine Price by Pipeline (2019-2024) & (USD/Dose)
- Table 17. Global Peptide Cancer Vaccine Sales by Pipeline (2025-2030) & (K Doses)
- Table 18. Global Peptide Cancer Vaccine Sales Market Share in Volume by Pipeline (2025-2030)
- Table 19. Global Peptide Cancer Vaccine Sales by Pipeline (2025-2030) & (US\$ Million)
- Table 20. Global Peptide Cancer Vaccine Sales Market Share in Value by Pipeline (2025-2030)
- Table 21. Global Peptide Cancer Vaccine Price by Pipeline (2025-2030) & (USD/Dose)
- Table 22. North America Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
- Table 23. North America Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (US\$ Million)
- Table 24. Europe Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)
- Table 25. Europe Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (US\$ Million)
- Table 26. Asia-Pacific Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)

Table 27. Asia-Pacific Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (US\$ Million)

Table 28. Latin America Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)

Table 29. Latin America Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (US\$ Million)

Table 30. Middle East and Africa Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (K Doses)

Table 31. Middle East and Africa Peptide Cancer Vaccine Sales by Pipeline (2019-2024) & (US\$ Million)

Table 32. Peptide Cancer Vaccine Industry Trends

Table 33. Peptide Cancer Vaccine Industry Drivers

Table 34. Peptide Cancer Vaccine Industry Opportunities and Challenges

Table 35. Peptide Cancer Vaccine Industry Restraints

Table 36. Global Peptide Cancer Vaccine Sales Revenue by Company (US\$ Million) & (2019-2024)

Table 37. Global Peptide Cancer Vaccine Revenue Market Share by Company (2019-2024)

Table 38. Global Peptide Cancer Vaccine Sales by Company (2019-2024) & (K Doses)

Table 39. Global Peptide Cancer Vaccine Sales Share by Company (2019-2024)

Table 40. Global Peptide Cancer Vaccine Market Price by Company (2019-2024) & (USD/Dose)

Table 41. Global Peptide Cancer Vaccine Industry Company Ranking, 2022 VS 2023 VS 2024

Table 42. Global Peptide Cancer Vaccine Key Company Manufacturing Sites & Headquarters

Table 43. Global Peptide Cancer Vaccine Company, Product Type & Application

Table 44. Global Peptide Cancer Vaccine Company Commercialization Time

Table 45. Global Company Market Concentration Ratio (CR5 and HHI)

Table 46. Global Peptide Cancer Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)

Table 47. Global Peptide Cancer Vaccine Market Size Comparison by Region (US\$ Million): 2019 VS 2023 VS 2030

Table 48. Global Peptide Cancer Vaccine Sales by Region (2019-2024) & (K Doses)

Table 49. Global Peptide Cancer Vaccine Sales Market Share in Volume by Region (2019-2024)

Table 50. Global Peptide Cancer Vaccine Sales by Region (2019-2024) & (US\$ Million)

Table 51. Global Peptide Cancer Vaccine Sales Market Share in Value by Region (2019-2024)



Table 52. Global Peptide Cancer Vaccine Sales (K Doses), Value (US\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 53. Global Peptide Cancer Vaccine Sales by Region (2025-2030) & (K Doses)

Table 54. Global Peptide Cancer Vaccine Sales Market Share in Volume by Region (2025-2030)

Table 55. Global Peptide Cancer Vaccine Sales by Region (2025-2030) & (US\$ Million)

Table 56. Global Peptide Cancer Vaccine Sales Market Share in Value by Region (2025-2030)

Table 57. Global Peptide Cancer Vaccine Sales (K Doses), Value (US\$ Million), Price (USD/Dose) and Gross Margin (2025-2030)

Table 58. Global Peptide Cancer Vaccine Sales by Application (2019 VS 2023 VS 2030) & (US\$ Million)

Table 59. Global Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)

Table 60. Global Peptide Cancer Vaccine Sales Market Share in Volume by Application (2019-2024)

Table 61. Global Peptide Cancer Vaccine Sales by Application (2019-2024) & (US\$ Million)

Table 62. Global Peptide Cancer Vaccine Sales Market Share in Value by Application (2019-2024)

Table 63. Global Peptide Cancer Vaccine Price by Application (2019-2024) & (USD/Dose)

Table 64. Global Peptide Cancer Vaccine Sales by Application (2025-2030) & (K Doses)

Table 65. Global Peptide Cancer Vaccine Sales Market Share in Volume by Application (2025-2030)

Table 66. Global Peptide Cancer Vaccine Sales by Application (2025-2030) & (US\$ Million)

Table 67. Global Peptide Cancer Vaccine Sales Market Share in Value by Application (2025-2030)

Table 68. Global Peptide Cancer Vaccine Price by Application (2025-2030) & (USD/Dose)

Table 69. North America Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)

Table 70. North America Peptide Cancer Vaccine Sales by Application (2019-2024) & (US\$ Million)

Table 71. Europe Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)

Table 72. Europe Peptide Cancer Vaccine Sales by Application (2019-2024) & (US\$

Million)

Table 73. Asia-Pacific Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)

Table 74. Asia-Pacific Peptide Cancer Vaccine Sales by Application (2019-2024) & (US\$ Million)

Table 75. Latin America Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)

Table 76. Latin America Peptide Cancer Vaccine Sales by Application (2019-2024) & (US\$ Million)

Table 77. Middle East and Africa Peptide Cancer Vaccine Sales by Application (2019-2024) & (K Doses)

Table 78. Middle East and Africa Peptide Cancer Vaccine Sales by Application (2019-2024) & (US\$ Million)

Table 79. Boston Biomedical Company Information

Table 80. Boston Biomedical Business Overview

Table 81. Boston Biomedical Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 82. Boston Biomedical Peptide Cancer Vaccine Product Portfolio

Table 83. Boston Biomedical Recent Development

Table 84. Ultimovacs Company Information

Table 85. Ultimovacs Business Overview

Table 86. Ultimovacs Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 87. Ultimovacs Peptide Cancer Vaccine Product Portfolio

Table 88. Ultimovacs Recent Development

Table 89. BrightPath Biotherapeutics Company Information

Table 90. BrightPath Biotherapeutics Business Overview

Table 91. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 92. BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio

Table 93. BrightPath Biotherapeutics Recent Development

Table 94. TapImmune Company Information

Table 95. TapImmune Business Overview

Table 96. TapImmune Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 97. TapImmune Peptide Cancer Vaccine Product Portfolio

Table 98. TapImmune Recent Development

Table 99. Immatix Company Information

Table 100. Immatix Business Overview

Table 101. Immatix Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 102. Immatix Peptide Cancer Vaccine Product Portfolio

Table 103. Immatix Recent Development

Table 104. Sellas Company Information

Table 105. Sellas Business Overview

Table 106. Sellas Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 107. Sellas Peptide Cancer Vaccine Product Portfolio

Table 108. Sellas Recent Development

Table 109. Imugene Company Information

Table 110. Imugene Business Overview

Table 111. Imugene Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 112. Imugene Peptide Cancer Vaccine Product Portfolio

Table 113. Imugene Recent Development

Table 114. VAXON Biotech Company Information

Table 115. VAXON Biotech Business Overview

Table 116. VAXON Biotech Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 117. VAXON Biotech Peptide Cancer Vaccine Product Portfolio

Table 118. VAXON Biotech Recent Development

Table 119. Generex Biotechnology Company Information

Table 120. Generex Biotechnology Business Overview

Table 121. Generex Biotechnology Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 122. Generex Biotechnology Peptide Cancer Vaccine Product Portfolio

Table 123. Generex Biotechnology Recent Development

Table 124. ISA Pharmaceuticals Company Information

Table 125. ISA Pharmaceuticals Business Overview

Table 126. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 127. ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio

Table 128. ISA Pharmaceuticals Recent Development

Table 129. OncoTherapy Science Company Information

Table 130. OncoTherapy Science Business Overview

Table 131. OncoTherapy Science Peptide Cancer Vaccine Sales (K Doses), Revenue (US\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 132. OncoTherapy Science Peptide Cancer Vaccine Product Portfolio

- Table 133. OncoTherapy Science Recent Development
- Table 134. North America Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (K Doses): 2019 VS 2023 VS 2030
- Table 135. North America Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
- Table 136. North America Peptide Cancer Vaccine Sales Market Share by Country (2019-2024)
- Table 137. North America Peptide Cancer Vaccine Sales Forecast by Country (2025-2030) & (K Doses)
- Table 138. North America Peptide Cancer Vaccine Sales Market Share Forecast by Country (2025-2030)
- Table 139. North America Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (US\$ Million): 2019 VS 2023 VS 2030
- Table 140. North America Peptide Cancer Vaccine Market Size by Country (2019-2024) & (US\$ Million)
- Table 141. North America Peptide Cancer Vaccine Market Share by Country (2019-2024)
- Table 142. North America Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030) & (US\$ Million)
- Table 143. North America Peptide Cancer Vaccine Market Share Forecast by Country (2025-2030)
- Table 144. Europe Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (K Doses): 2019 VS 2023 VS 2030
- Table 145. Europe Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)
- Table 146. Europe Peptide Cancer Vaccine Sales Market Share by Country (2019-2024)
- Table 147. Europe Peptide Cancer Vaccine Sales Forecast by Country (2025-2030) & (K Doses)
- Table 148. Europe Peptide Cancer Vaccine Sales Market Share Forecast by Country (2025-2030)
- Table 149. Europe Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (US\$ Million): 2019 VS 2023 VS 2030
- Table 150. Europe Peptide Cancer Vaccine Market Size by Country (2019-2024) & (US\$ Million)
- Table 151. Europe Peptide Cancer Vaccine Market Share by Country (2019-2024)
- Table 152. Europe Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030) & (US\$ Million)
- Table 153. Europe Peptide Cancer Vaccine Market Share Forecast by Country (2025-2030)

Table 154. Asia-Pacific Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (K Doses): 2019 VS 2023 VS 2030

Table 155. Asia-Pacific Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)

Table 156. Asia-Pacific Peptide Cancer Vaccine Sales Market Share by Country (2019-2024)

Table 157. Asia-Pacific Peptide Cancer Vaccine Sales Forecast by Country (2025-2030) & (K Doses)

Table 158. Asia-Pacific Peptide Cancer Vaccine Sales Market Share Forecast by Country (2025-2030)

Table 159. Asia-Pacific Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (US\$ Million): 2019 VS 2023 VS 2030

Table 160. Asia-Pacific Peptide Cancer Vaccine Market Size by Country (2019-2024) & (US\$ Million)

Table 161. Asia-Pacific Peptide Cancer Vaccine Market Share by Country (2019-2024)

Table 162. Asia-Pacific Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030) & (US\$ Million)

Table 163. Asia-Pacific Peptide Cancer Vaccine Market Share Forecast by Country (2025-2030)

Table 164. Latin America Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (K Doses): 2019 VS 2023 VS 2030

Table 165. Latin America Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)

Table 166. Latin America Peptide Cancer Vaccine Sales Market Share by Country (2019-2024)

Table 167. Latin America Peptide Cancer Vaccine Sales Forecast by Country (2025-2030) & (K Doses)

Table 168. Latin America Peptide Cancer Vaccine Sales Market Share Forecast by Country (2025-2030)

Table 169. Latin America Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (US\$ Million): 2019 VS 2023 VS 2030

Table 170. Latin America Peptide Cancer Vaccine Market Size by Country (2019-2024) & (US\$ Million)

Table 171. Latin America Peptide Cancer Vaccine Market Share by Country (2019-2024)

Table 172. Latin America Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030) & (US\$ Million)

Table 173. Latin America Peptide Cancer Vaccine Market Share Forecast by Country (2025-2030)

Table 174. Middle East and Africa Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (K Doses): 2019 VS 2023 VS 2030

Table 175. Middle East and Africa Peptide Cancer Vaccine Sales by Country (2019-2024) & (K Doses)

Table 176. Middle East and Africa Peptide Cancer Vaccine Sales Market Share by Country (2019-2024)

Table 177. Middle East and Africa Peptide Cancer Vaccine Sales Forecast by Country (2025-2030) & (K Doses)

Table 178. Middle East and Africa Peptide Cancer Vaccine Sales Market Share Forecast by Country (2025-2030)

Table 179. Middle East and Africa Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country (US\$ Million): 2019 VS 2023 VS 2030

Table 180. Middle East and Africa Peptide Cancer Vaccine Market Size by Country (2019-2024) & (US\$ Million)

Table 181. Middle East and Africa Peptide Cancer Vaccine Market Share by Country (2019-2024)

Table 182. Middle East and Africa Peptide Cancer Vaccine Market Size Forecast by Country (2025-2030) & (US\$ Million)

Table 183. Middle East and Africa Peptide Cancer Vaccine Market Share Forecast by Country (2025-2030)

Table 184. Key Raw Materials

Table 185. Raw Materials Key Suppliers

Table 186. Peptide Cancer Vaccine Distributors List

Table 187. Peptide Cancer Vaccine Customers List

Table 188. Research Programs/Design for This Report

Table 189. Authors List of This Report

Table 190. Secondary Sources

Table 191. Primary Sources

## List Of Figures

### LIST OF FIGURES

- Figure 1. Peptide Cancer Vaccine Product Picture
- Figure 2. Global Peptide Cancer Vaccine Market Size (US\$ Million), 2019 VS 2023 VS 2030
- Figure 3. Global Peptide Cancer Vaccine Market Size (2019-2030) & (US\$ Million)
- Figure 4. Global Peptide Cancer Vaccine Sales (2019-2030) & (K Doses)
- Figure 5. Product Picture of ITK-1
- Figure 6. Global ITK-1 Sales YoY Growth (2019-2030) & (K Doses)
- Figure 7. Product Picture of GRN-1201
- Figure 8. Global GRN-1201 Sales YoY Growth (2019-2030) & (K Doses)
- Figure 9. Product Picture of TPIV200
- Figure 10. Global TPIV200 Sales YoY Growth (2019-2030) & (K Doses)
- Figure 11. Product Picture of TPIV110
- Figure 12. Global TPIV110 Sales YoY Growth (2019-2030) & (K Doses)
- Figure 13. Product Picture of UV1
- Figure 14. Global UV1 Sales YoY Growth (2019-2030) & (K Doses)
- Figure 15. Product Picture of Galinpepimut-S
- Figure 16. Global Galinpepimut-S Sales YoY Growth (2019-2030) & (K Doses)
- Figure 17. Product Picture of TARP 27-35
- Figure 18. Global TARP 27-35 Sales YoY Growth (2019-2030) & (K Doses)
- Figure 19. Product Picture of HER-Vaxx
- Figure 20. Global HER-Vaxx Sales YoY Growth (2019-2030) & (K Doses)
- Figure 21. Product Picture of Vx-001
- Figure 22. Global Vx-001 Sales YoY Growth (2019-2030) & (K Doses)
- Figure 23. Product Picture of Others
- Figure 24. Global Others Sales YoY Growth (2019-2030) & (K Doses)
- Figure 25. Global Peptide Cancer Vaccine Market Size Overview by Type (2019-2030) & (US\$ Million)
- Figure 26. Global Peptide Cancer Vaccine Market Share by Type 2023 VS 2030
- Figure 27. North America Peptide Cancer Vaccine Sales Market Share in Volume by Type in 2023
- Figure 28. North America Peptide Cancer Vaccine Sales Market Share in Value by Type in 2023
- Figure 29. Europe Peptide Cancer Vaccine Sales Market Share in Volume by Type in 2023
- Figure 30. Europe Peptide Cancer Vaccine Sales Market Share in Value by Type in

2023

Figure 31. Asia-Pacific Peptide Cancer Vaccine Sales Market Share in Volume by Type in 2023

Figure 32. Asia-Pacific Peptide Cancer Vaccine Sales Market Share in Value by Type in 2023

Figure 33. Latin America Peptide Cancer Vaccine Sales Market Share in Volume by Type in 2023

Figure 34. Latin America Peptide Cancer Vaccine Sales Market Share in Value by Type in 2023

Figure 35. Middle East and Africa Peptide Cancer Vaccine Sales Market Share in Volume by Type in 2023

Figure 36. Middle East and Africa Peptide Cancer Vaccine Sales Market Share in Value by Type in 2023

Figure 37. Global Top 5 and 10 Peptide Cancer Vaccine Players Market Share by Revenue in 2023

Figure 38. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 39. Product Picture of Breast Cancer

Figure 40. Global Breast Cancer Sales YoY Growth (2019-2030) & (K Doses)

Figure 41. Product Picture of Lung Cancer

Figure 42. Global Lung Cancer Sales YoY Growth (2019-2030) & (K Doses)

Figure 43. Product Picture of Melanoma

Figure 44. Global Melanoma Sales YoY Growth (2019-2030) & (K Doses)

Figure 45. Product Picture of Prostate Cancer

Figure 46. Global Prostate Cancer Sales YoY Growth (2019-2030) & (K Doses)

Figure 47. Product Picture of Others

Figure 48. Global Others Sales YoY Growth (2019-2030) & (K Doses)

Figure 49. Global Peptide Cancer Vaccine Market Size Overview by Application (2019-2030) & (US\$ Million)

Figure 50. Global Peptide Cancer Vaccine Market Share by Application 2023 VS 2030

Figure 51. North America Peptide Cancer Vaccine Sales Market Share in Volume by Application in 2023

Figure 52. North America Peptide Cancer Vaccine Sales Market Share in Value by Application in 2023

Figure 53. Europe



## I would like to order

Product name: Global Peptide Cancer Vaccine Market Size, Manufacturers, Opportunities and Forecast to 2030

Product link: <https://marketpublishers.com/r/GE302F0E81F8EN.html>

Price: US\$ 3,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE302F0E81F8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

